Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
Public ClinicalTrials.gov record NCT06596252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double-blind, Randomized, Non-inferiority Phase III Trial on the Efficacy and Tolerability of 2 mg Once Daily vs. 1 mg Twice Daily Budesonide Orodispersible Tablets in Adults With Eosinophilic Esophagitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Study identification
- NCT ID
- NCT06596252
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 308 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2021
- Primary completion
- Nov 30, 2026
- Completion
- Feb 29, 2028
- Last update posted
- Aug 27, 2026
2021 – 2028
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dr. Falk Investigational Site | Scottsdale | Arizona | 85259 | — |
| Dr. Falk Investigational Site | Little Rock | Arkansas | 72205 | — |
| Dr. Falk Investigational Site | La Jolla | California | 92037 | — |
| Dr. Falk Investigational Site | San Diego | California | 92193 | — |
| Dr. Falk Investigational Site | Doral | Florida | 83706 | — |
| Dr. Falk Investigational Site | New Port Richey | Florida | 34653 | — |
| Dr. Falk Investigational Site | Boise | Idaho | 83706 | — |
| Dr. Falk Investigational Site | Boston | Massachusetts | 02111 | — |
| Wyoming | Ann Arbor | Michigan | 48109 | — |
| Dr. Falk Investigational Site | Wyoming | Michigan | 49519 | — |
| Dr. Falk Investigational Site | Rochester | Minnesota | 55905 | — |
| Dr. Falk Investigational Site | Freehold | New Jersey | 07728 | — |
| Dr. Falk Investigational Site | New York | New York | 10075 | — |
| Dr. Falk Investigational Site | Chapel Hill | North Carolina | 27599-7080 | — |
| Dr. Falk Investigational Site | Cleveland | Ohio | 44195 | — |
| Dr. Falk Investigational Site | Mentor | Ohio | 44060 | — |
| Wyoming | Philadelphia | Pennsylvania | 19104 | — |
| Dr. Falk Investigational Site | Harlingen | Texas | 78550 | — |
| Dr. Falk Investigational Site | Salt Lake City | Utah | 85259 | — |
| Dr. Falk Investigational Site | Lynchburg | Virginia | 24502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06596252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06596252 live on ClinicalTrials.gov.